key: cord-0700753-dl5kfo3k
authors: Chen, R. E.; Gorman, M. J.; Zhu, D. Y.; Carreno, J. M.; Yuan, D.; VanBlargan, L. A.; Burdess, S.; Lauffenburger, D. A.; Kim, W.; Turner, J. S.; Droit, L.; Handley, S. A.; Chahin, S.; Deepak, P.; O'Halloran, J.; Paley, M.; Presti, R.; Wu, G. F.; Krammer, F.; Alter, G.; Ellebedy, A.; Kim, A. H.; Diamond, M. S.
title: Reduced antibody activity against SARS-CoV-2 B.1.617.2 Delta virus in serum of mRNA-vaccinated patients receiving TNF-alpha inhibitors
date: 2021-09-29
journal: nan
DOI: 10.1101/2021.09.28.21264250
sha: 2d90b06c533b258dcf7d28c869a91cd0d5e6bb10
doc_id: 700753
cord_uid: dl5kfo3k

Although vaccines effectively prevent COVID-19 in healthy individuals, they appear less immunogenic in individuals with chronic inflammatory diseases (CID) and/or under chronic immunosuppression, and there is uncertainty of their activity against emerging variants of concern in this population. Here, we assessed a cohort of 74 CID patients treated as monotherapy with chronic immunosuppressive drugs for functional antibody responses in serum against historical and variant SARS-CoV-2 viruses after immunization with Pfizer mRNA BNT162b2 vaccine. Longitudinal analysis showed the greatest reductions in neutralizing antibodies and Fc effector function capacity in individuals treated with TNF-alpha inhibitors, and this pattern appeared worse against the B.1.617.2 Delta virus. Within five months of vaccination, serum neutralizing titers of the majority of CID patients fell below the presumed threshold correlate for antibody-mediated protection. Thus, further vaccine boosting or administration of long-acting prophylaxis (e.g., monoclonal antibodies) likely will be required to prevent SARS-CoV-2 infection in this susceptible population.

Although vaccines effectively prevent COVID-19 in healthy individuals, they appear less 27 immunogenic in individuals with chronic inflammatory diseases (CID) and/or under chronic 28 immunosuppression, and there is uncertainty of their activity against emerging variants of 29 concern in this population. Here, we assessed a cohort of 74 CID patients treated as monotherapy 2 strains, the emergence of variants of concern (VOC) has prompted questions as to whether they 47 will retain efficacy. 48 SARS-CoV-2 spike protein engages cell-surface receptor angiotensin-converting enzyme 49 2 (ACE2) for attachment and entry into human cells (Letko et al., 2020) . The S1 component of too few patients enrolled to interpret trends, but as expected, patients receiving BCDT had low 118 levels of IgG against the spike proteins (Fig S1) . 119

To begin to determine the functional capacity of the antibody response, we interrogated 120 sera obtained from immunocompetent volunteers (n = 25) and CID patients (n = 74) three 121 months after their second dose of BNT162b2 mRNA vaccine. As a group, sera from CID 122 patients trended towards lower neutralizing activity, although comparisons did not attain 123 statistical significance (WA1/2020 D614G (Geometric mean titer [ (Fig 2A-B) . In both control and CID 127 patient groups, the B.1.351 and B.1.617.2 variants were neutralized less efficiently than the 128 historical WA1/2020 D614G strain, as reported previously (Chen et (Fig 2A and D) . Other treatment groups (n > 5) including antimalarial, 133 anti-integrin, NSAIDs, and anti-IL-23 inhibitors had similar neutralization titers to 134 immunocompetent volunteers (Fig 2A and E-H) . In addition, all subgroups with n > 5 135 neutralized Wash-B.1.351 and B.1.617.2 less efficiently than WA1/2020 (Fig 2A-H) . These 136 trends in neutralization titers also were seen in groups receiving other immunosuppressive agents 137 with smaller number of individuals (Fig S2) . 138 A recent study analyzing the relationship between in vitro neutralization titers and 139 protection against SARS-CoV-2 infection by vaccines estimated a protective serum titer of 1/54 140 (range 1/10 to 1/200 depending on the assay used) (Khoury et al., 2021) . Given this result, we 141 determined the fraction of individuals in the different groups of our cohort that fell below this 142 cut-off. Three months after the completion of the initial series of BNT162b2 mRNA vaccine, 143 only 2 of 25 (8%) immunocompetent volunteers had neutralizing titers (NT 50 ) below 1/50 against 144 B.1.617.2, whereas 30 of 74 (35%) of CID patients had titers below this level ( Table 2) . Many of 145 the drug treatment groups also had a higher percentage of individuals below the 1/50 cut-off than 146 immunocompetent volunteers including antimetabolites (33%), TNFi (64%), antimalarial agents 147 (30%), NSAIDs (11%), and anti-IL-23 inhibitor (22%) ( Table 2) . 148

We separately grouped the individuals by disease and re-analyzed neutralization titers at 149 three months after second vaccination. Some patient groups with certain diseases (e.g., ulcerative 150

colitis, systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, and asthma) had 151 neutralization titers that were similar to immunocompetent volunteers (Fig 2A and S3) (Fig S3) . Compared to 34% of all CID patients at 3 months after 160 second vaccination that had a neutralization titer of less than 1/50 against B.1.617.2, 50% of 161 Crohn's disease patients fell below this threshold (Fig S3) . Moreover, 63% of Crohn's disease 162 patients receiving TNFi had neutralization titers against B.1.617.2 below the 1/50 cut-off 163 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 29, 2021. ; https://doi.org/10.1101/2021.09.28.21264250 doi: medRxiv preprint compared to 43% of those on other treatment regimens (Fig S3) (Fig 3 and S4) . There 176 were no differences in levels of IgG1, IgG3, and IgM against SARS-CoV-2 spike proteins, and 177

C1q or FcγR (FcγR2A, FcγR2B, or FcγR3A) binding (Fig 3 and S4) . However, compared to 178 immunocompetent volunteers, patients treated with TNFi had decreased anti-SARS-CoV-2 IgG, 179

IgG2, and IgG4 levels against Wuhan-1 D614G (Fig 3A) , B.1.617.2 (Fig 3B) , and B.1.351 (Fig  180   S4 ) whereas all other groups had no significant difference. We also assessed for antibody-181 mediated innate immune effector functions. While all groups showed similar antibody-dependent 182 neutrophil phagocytosis (ADNP) (Fig 3C-D and S4 ), patients receiving TNFi had decreased 183 antibody-dependent cellular phagocytosis (ADCP) against B.1.617.2 (Fig 3D) and B.1.351 (Fig  184   S3 ). For unexplained reasons, patients receiving anti-integrin inhibitors had enhanced ADCP 185 against Wuhan-1 D614G (Fig 3C) and antibody-dependent complement fixation (ADCD) 186 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 29, 2021. ; https://doi.org/10.1101/2021.09.28.21264250 doi: medRxiv preprint against B.1.617.2 (Fig 3D) and B.1.351 (Fig S4) . When we combined the data, only patients 187 receiving TNFi showed substantive decreases in antibody effector functions at three months after 188 second vaccination (Fig 3E) . Table 2) . 208 209 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 29, 2021. ; https://doi.org/10.1101/2021.09.28.21264250 doi: medRxiv preprint described previously (Chen et al., 2021b) . The B.1.617.2 isolate was obtained a gift from R. 463

Webby (Memphis, TN). All viruses were passaged once in Vero-TMPRSS2 cells and subjected 464 to next-generation sequencing after RNA extraction to confirm the introduction and stability of 465 substitutions ( Table S1) Antigens were coupled to magnetic Luminex beads (Luminex Corp) by carbodiimide-NHS ester-506 coupling (Thermo Fisher). Antigen-coupled microspheres were washed and incubated with 507 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 29, 2021. ; https://doi.org/10.1101/2021.09.28.21264250 doi: medRxiv preprint plasma or serum samples at an appropriate sample dilution (1:5000 for IgG1 and all low affinity 508 FcγR, and 1:200 for all other readouts) for 2 h at 37°C in 384-well plates (Greiner Bio-One). 509

Unbound antibodies were washed away, and antigen-bound antibodies were detected by using a 510 PE-coupled detection antibody for each subclass and isotype (IgG1, IgG3, IgA1, and IgM; 511 Southern Biotech), and FcγR were fluorescently labeled with PE before addition to immune 512 complexes (FcγR2a, FcγR3a; Duke Protein Production facility). After one hour of incubation, 513 plates were washed, and flow cytometry was performed with an iQue (Intellicyt) and analyzed 514 using IntelliCyt ForeCyt (v8.1). PE median fluorescent intensity (MFI) is reported as a readout 515 for antigen-specific antibody titers. 516

Antibody-dependent complement deposition (ADCD) Antibody-dependent 517 complement deposition (ADCD) was conducted as previously described (Fischinger et al., 2019) . 518

Briefly, SARS-CoV-2 antigens were coupled to magnetic Luminex beads (Luminex Corp) by 519 carbodiimide-NHS ester-coupling (Thermo Fisher). Coupled beads were incubated for 2 h at 520 37°C with serum samples (1:10 dilution) to form immune complexes and then washed to remove 521 unbound immunoglobulins. To measure antibody-dependent deposition of C3, lyophilized 522 guinea pig complement (Cedarlane) was diluted in gelatin veronal buffer with calcium and 523 magnesium (GBV++) (Boston BioProducts) and added to immune complexes. Subsequently, C3 524 was detected with an anti-C3 fluorescein-conjugated goat IgG fraction detection antibody 525 (Mpbio). Flow cytometry was performed 5 Laser LSR Fortessa Flow Cytometer and analyzed 526 using FlowJo V10.7.1. ADCD was reported as the median of C3 deposition. 527

Antibody-dependent cellular phagocytosis (ADCP) and antibody-dependent neutrophil 529 phagocytosis (ADNP) were conducted according to the previously described protocols (Butler et 530 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The data used to generate Fig 3e was graphed and analyzed using Python version 3.8.5 and the 550 'plotly' package (Sievert, 2020) . For each feature, data was first standardized by computing the 551 Z-score, scaling values to zero mean and unit variance. The median resulting values are 552 represented on each polar plot. All other data were graphed and analyzed in GraphPad Prism 553 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 29, 2021. ; https://doi.org/10.1101/2021.09.28.21264250 doi: medRxiv preprint v8.4.3. Tobit linear regression was performed using Stata/MP 13.1, and the effects were refined 554 to account for left-censoring of data below the limit of detection (LoD). 555 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 29, 2021. ; https://doi.org/10.1101/2021.09.28.21264250 doi: medRxiv preprint Table 1. Patient characteristics  556  557  558  559  560  561  562  563  564  565  566  567  568  569  570  571  572  573  574  575  576  577  578  579  580  581  582  583  584  585  586  587  588  589  590  591  592  593  594  595  596  597 a Patients may have more than one disease diagnosis. 598 599 600 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint Anti-integrin 10 0 (0) 1 (10) 0 (0) 3 0 (0) 0 (0) 1 (33) NSAIDs 9 1 (11) 1 (11) 1 (11) 5 1 (20) 2 (40) 2 (40)

Anti-IL-23 9 1 (11) 2 (22) 2 (22) 3 0 (0) 1 (33) 1 (33)

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 29, 2021. ; https://doi.org/10.1101/2021.09.28.21264250 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 29, 2021. ; https://doi.org/10.1101/2021.09.28.21264250 doi: medRxiv preprint

In vivo monoclonal antibody efficacy against SARS-669

CoV-2 variant strains

Resistance of SARS-CoV-2 variants to neutralization by 673 monoclonal and serum-derived polyclonal antibodies

Persistence and Evolution of SARS-CoV-2 in an 677 Immunocompromised Host

SARS-CoV-2 evolution in an 681 immunocompromised host reveals shared neutralization escape mechanisms

Immune correlates of protection by mRNA-1273 686 vaccine against SARS-CoV-2 in nonhuman primates

mRNA-1273 protects against SARS-CoV-2 beta 690 infection in nonhuman primates

Serological response to the 2009 693 H1N1 influenza vaccination in patients with inflammatory bowel disease

Antibody Responses to SARS-CoV-2 696 after Infection or Vaccination in Children and Young Adults with Inflammatory Bowel Disease. 697 medRxiv

Effect of Immunosuppression on the 701 Immunogenicity of mRNA Vaccines to SARS-CoV-2 : A Prospective Cohort Study

Decreased Immune 706 Response to COVID-19 mRNA Vaccine in Patients with Inflammatory Bowel Diseases Treated 707 with Anti TNFα. medRxiv

Effects of immunosuppression on immune 711 response to pneumococcal vaccine in inflammatory bowel disease: a prospective study

A high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies 716 to induce complement activation

Protective antibodies elicited by SARS-720

CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates

Development and maturation of secondary lymphoid 724 tissues

Fab and Fc contribute to maximal protection 728 against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination

Humoral and cellular immune response and 733 safety of two-dose SARS-CoV-2 mRNA-1273 vaccine in solid organ transplant recipients

High dose hepatitis B vaccine is not effective in patients 737 using immunomodulatory drugs: a pilot study

Effect of methotrexate, anti-tumor 739 necrosis factor α , and rituximab on the immune response to influenza and pneumococcal 740 vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis

Large-scale study of antibody titer decay following 745 BNT162b2 mRNA vaccine or SARS-CoV-2 infection

Three 748 Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients

Subtle immunological differences in mRNA-753 1273 and BNT162b2 COVID-19 vaccine induced Fc-functional profiles

A versatile high-throughput assay to 756 characterize antibody-mediated neutrophil phagocytosis

Anti-SARS-CoV-2 antibody responses 760 are attenuated in patients with IBD treated with infliximab

Neutralizing antibody levels are highly 764 predictive of immune protection from symptomatic SARS-CoV-2 infection

SARS-CoV-2 growth, furin-769 cleavage-site adaptation and neutralization using serum from acutely infected hospitalized 770 COVID-19 patients

Functional assessment of cell entry and receptor 773 usage for SARS-CoV-2 and other lineage B betacoronaviruses

1.617 by vaccine and convalescent serum

BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 781 variants

Neutralizing Activity of BNT162b2-Elicited Serum

Identification of SARS-CoV-2 spike 789 mutations that attenuate monoclonal and serum antibody neutralization

Effectiveness of Covid-19 Vaccines against 794 the B.1.617.2 (Delta) Variant

Efficacy of the

Covid-19 Vaccine against the B.1.351 Variant

SARS-CoV-2 immune evasion by

Janeway's immunobiology (Garland science)

Efficacy of hepatitis A vaccination and factors impacting 808 on seroconversion in patients with inflammatory bowel disease

Cross-neutralization of SARS-CoV-2 by a 812 human monoclonal SARS-CoV antibody

CoV-2 variant Delta to antibody neutralization

Spike mutation D614G alters SARS-CoV-2 820 fitness

Antibody Response to Hepatitis B Virus Vaccine is Impaired in 824 Patients With Inflammatory Bowel Disease on Infliximab Therapy

Risk of Breakthrough SARS-CoV-2 829 Infections in Adult Transplant Recipients

Safety and Efficacy of Single-Dose 833

S Vaccine against Covid-19

Antibody potency, effector function, 837 and combinations in protection and therapy for SARS-CoV-2 infection in vivo

Pandemic 839 Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19

A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

Cross-reactive coronavirus antibodies 848 with diverse epitope specificities and Fc effector functions

Efficacy of NVX-CoV2373 Covid-19 Vaccine 852 against the B.1.351 Variant

Immunogenicity of Quadrivalent Influenza Vaccine for 856 Patients with Inflammatory Bowel Disease Undergoing Immunosuppressive Therapy

Interactive Web-Based Data Visualization with R, plotly, and shiny

SARS-CoV-2 Seroconversion in 862 Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup

Neutralizing and protective human 867 monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein

Neutralization of viruses with European, South African, and United States 872 SARS-CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA vaccine-873 elicited antibodies

Safety and Efficacy of the BNT162b2 877 mRNA Covid-19 Vaccine through 6 Months

SARS-CoV-2 mRNA vaccines induce persistent human 881 germinal centre responses

Live imaging of SARS-CoV-2 infection in 885 mice reveals that neutralizing antibodies require Fc function for optimal efficacy

A potently neutralizing SARS-CoV-2 antibody inhibits variants 890 of concern by utilizing unique binding residues in a highly conserved epitope

Increased resistance of SARS-CoV-2 variant P.1 to antibody 894 neutralization

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. 898

SARS-CoV-2 902 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

Human neutralizing antibodies against SARS-CoV-2 906 require intact Fc effector functions for optimal therapeutic protection

Fc-engineered antibody therapeutics with 911 improved anti-SARS-CoV-2 efficacy

TMPRSS2 and TMPRSS4 promote 915 SARS-CoV-2 infection of human small intestinal enterocytes

Compromised Humoral Functional Evolution Tracks

CoV-2 Mortality

Rapid isolation and profiling of a diverse panel of 923 human monoclonal antibodies targeting the SARS-CoV-2 spike protein